OncoTherapy Science (4564) · RiskFirst statedLatest Occurring Fact (2026-05-08): "Materialised"
Foreign exchange risk associated with overseas research and clinical trials
First written in FY2018. 1 of 2 entries say "Materialised", first in 2026-05-08. Latest entry: 2026-05-08.
2entries
9years
1from disclosures
How it moved
Same theme, other companies
Foreign exchange risk associated with overseas research, clinical trials and outsourcingA theme 2 companies write about · 2 as a headwind · 0 as a tailwind
OncoTherapy Science moved to the "Worse" side of this theme in 2026.
1 other company's latest entry also says "Materialised".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- 2026-05-08MaterialisedOccurring Fact
「In addition, the Company recognized a foreign exchange loss of ¥2 million on foreign-currency-denominated liabilities resulting from exchange-rate movements.」
A foreign exchange loss of ¥2 million resulting from exchange-rate movements was recognized on foreign-currency-denominated liabilities. Foreign exchange risk materialized in the results. - FY2018First statedAnnual report
「In addition to Japan, the Group actively conducts joint research and outsourcing transactions with overseas companies, universities and research institutions, including through clinical trials in the United States.」
The Group newly disclosed foreign exchange fluctuation risk associated with overseas clinical trials, joint research and outsourcing, as well as the possibility that such risk cannot be fully avoided through forward exchange contracts or other measures.